These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist. Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035 [TBL] [Abstract][Full Text] [Related]
4. Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress. Ganon-Elazar E; Akirav I Neuropsychopharmacology; 2012 Jan; 37(2):456-66. PubMed ID: 21918506 [TBL] [Abstract][Full Text] [Related]
5. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway. Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229 [TBL] [Abstract][Full Text] [Related]
6. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2. Pandolfo P; Pamplona FA; Prediger RD; Takahashi RN Eur J Pharmacol; 2007 Jun; 563(1-3):141-8. PubMed ID: 17374533 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model. Lefever TW; Marusich JA; Antonazzo KR; Wiley JL Pharmacol Biochem Behav; 2014 Mar; 118():30-5. PubMed ID: 24412835 [TBL] [Abstract][Full Text] [Related]
8. Effects of Adolescent Cannabinoid Self-Administration in Rats on Addiction-Related Behaviors and Working Memory. Kirschmann EK; Pollock MW; Nagarajan V; Torregrossa MM Neuropsychopharmacology; 2017 Apr; 42(5):989-1000. PubMed ID: 27582345 [TBL] [Abstract][Full Text] [Related]
9. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Fattore L; Cossu G; Martellotta CM; Fratta W Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718 [TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Guidali C; Viganò D; Petrosino S; Zamberletti E; Realini N; Binelli G; Rubino T; Di Marzo V; Parolaro D Int J Neuropsychopharmacol; 2011 Feb; 14(1):17-28. PubMed ID: 20196921 [TBL] [Abstract][Full Text] [Related]
11. Dose-response effect of acute phencyclidine on functional connectivity and dopamine levels, and their association with schizophrenia-like symptom classes in rat. Paasonen J; Salo RA; Ihalainen J; Leikas JV; Savolainen K; Lehtonen M; Forsberg MM; Gröhn O Neuropharmacology; 2017 Jun; 119():15-25. PubMed ID: 28342897 [TBL] [Abstract][Full Text] [Related]
12. Analysis of licking microstructure provides no evidence for a reduction in reward value following acute or sub-chronic phencyclidine administration. Lydall ES; Gilmour G; Dwyer DM Psychopharmacology (Berl); 2010 Apr; 209(2):153-62. PubMed ID: 20145910 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756 [TBL] [Abstract][Full Text] [Related]
14. Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia. Gomes FV; Guimarães FS; Grace AA Int J Neuropsychopharmacol; 2014 Dec; 18(2):. PubMed ID: 25522381 [TBL] [Abstract][Full Text] [Related]
15. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance. Pedersen CS; Goetghebeur P; Dias R J Neurosci Methods; 2009 Dec; 185(1):66-9. PubMed ID: 19761795 [TBL] [Abstract][Full Text] [Related]
16. Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain. Almeida V; Peres FF; Levin R; Suiama MA; Calzavara MB; Zuardi AW; Hallak JE; Crippa JA; Abílio VC Schizophr Res; 2014 Mar; 153(1-3):150-9. PubMed ID: 24556469 [TBL] [Abstract][Full Text] [Related]
17. Peripheral and intra-dorsolateral striatum injections of the cannabinoid receptor agonist WIN 55,212-2 impair consolidation of stimulus-response memory. Goodman J; Packard MG Neuroscience; 2014 Aug; 274():128-37. PubMed ID: 24838065 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of protective effects of non-selective cannabinoid receptor agonist WIN 55,212-2 against the nitroglycerine-induced acute and chronic animal models of migraine: A mechanistic study. Mohammadi Vosough E; Baradaran Rahimi V; Masoud SA; Mirkarimi HR; Demneh MK; Abed A; Banafshe HR; Askari VR Life Sci; 2019 Sep; 232():116670. PubMed ID: 31330139 [TBL] [Abstract][Full Text] [Related]
19. Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period. Rudenko V; Rafiuddin A; Leheste JR; Friedman LK Pharmacol Biochem Behav; 2012 Jan; 100(3):474-84. PubMed ID: 22019959 [TBL] [Abstract][Full Text] [Related]
20. Δ9-tetrahydrocannabinol (Δ9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice. Rodríguez G; Neugebauer NM; Yao KL; Meltzer HY; Csernansky JG; Dong H Pharmacol Biochem Behav; 2017 Aug; 159():6-11. PubMed ID: 28648819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]